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Abstract
Cerebral spinal fluid (CSF) Aβ42, tau and p181tau are widely accepted biomarkers of Alzheimer’s disease (AD).
Numerous studies show that CSF tau and p181tau levels are elevated in mild-to-moderate AD compared to age-
matched controls. In addition, these increases might predict preclinical AD in cognitively normal elderly. Despite their
importance as biomarkers, the molecular nature of CSF tau and ptau is not known. In the current study, reverse-
phase high performance liquid chromatography was used to enrich and concentrate tau prior to western-blot
analysis. Multiple N-terminal and mid-domain fragments of tau were detected in pooled CSF with apparent sizes
ranging from <20 kDa to ~40 kDa. The pattern of tau fragments in AD and control samples were similar. In contrast,
full-length tau and C-terminal-containing fragments were not detected. To quantify levels, five tau ELISAs and three
ptau ELISAs were developed to detect different overlapping regions of the protein. The discriminatory potential of
each assay was determined using 20 AD and 20 age-matched control CSF samples. Of the tau ELISAs, the two
assays specific for tau containing N-terminal sequences, amino acids 9-198 (numbering based on tau 441) and
9-163, exhibited the most significant differences between AD and control samples. In contrast, CSF tau was not
detected with an ELISA specific for a more C-terminal region (amino acids 159-335). Significant discrimination was
also observed with ptau assays measuring amino acids 159-p181 and 159-p231. Interestingly, the discriminatory
potential of p181 was reduced when measured in the context of tau species containing amino acids 9-p181. Taken
together, these results demonstrate that tau in CSF occurs as a series of fragments and that discrimination of AD
from control is dependent on the subset of tau species measured. These assays provide novel tools to investigate
CSF tau and ptau as biomarkers for other neurodegenerative diseases.
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Introduction
Alzheimer’s disease (AD) is the most common form of
dementia and the sixth leading cause of death in the US.
Estimates indicate that ~5 million people in the US currently
have the disease and that number is expected to increase up
to ~16 million by 2050. Current therapeutic options are limited
to symptomatic treatments highlighting the urgent need to
develop and evaluate novel disease-modifying approaches.
Identification of sensitive and specific AD biomarkers will be
critical for the development of these therapeutics.
Over the past two decades, extensive effort has focused on
the identification and development of AD biomarkers
specifically linked to disease pathology (reviewed in 1). The
major histopathological features of AD are senile plaques and
neurofibrillary tangles (NFT) (reviewed in 2). Senile plaques are
comprised of extracellular deposits of Aβ peptides, primarily
Aβ42, which are generated by proteolytic processing of the
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amyloid precursor protein. NFTs are formed from the
aggregation of hyperphosphorylated tau, a protein normally
associated with microtubules. Numerous studies show that
cerebral spinal fluid (CSF) Aβ42 levels decrease to around half
the level in controls while CSF tau and p181tau levels increase
around 2-3 fold in mild-moderate AD patients compared to age-
matched controls (e.g. [3,4,5]). In addition to p181tau,
measures of other phospho-epitopes, including p199, p212/
p214, p231, p231/p235, p396/p404, have also been reported to
be increased in AD relative to age-matched controls
[6,7,8,9,10,11]. Changes in Aβ42, tau and p181tau are evident
many years prior to onset of dementia and are predictive of
conversion to mild AD [3,4,12,13,14,15].
The decrease in CSF Aβ42 observed in AD patients is
thought to reflect increased binding and sequestration of Aβ42
in senile plaques present in the diseased brain
[16,17,18,19,20]. In contrast, multiple mechanisms have been
proposed to explain increased CSF tau and ptau in AD. For
example, CSF tau levels in stroke, traumatic brain injury and
Creutzfeldt–Jakob disease increase rapidly and dramatically
likely due to acute neuronal cell death [21,22,23,24].
Interestingly, these increases in CSF tau are not associated
with any change in CSF pTau (e.g. [24,25]), suggesting that
CSF pTau is not a general marker for neuronal damage or
degeneration. Neuron cell loss is also a hallmark of AD and
thus could explain some of the increases in CSF tau; however,
cell loss develops relatively slowly in AD and thus is unlikely to
be the only cause. Moreover, increases in CSF tau are not
detected in other neurodegenerative diseases despite ongoing
neuronal cell loss (e.g. PD, FTD). Recent evidence from in vitro
studies indicates that tau can be actively secreted from cells
[26,27,28,29,30,31]. Such a secretion process could help
explain the presence of CSF tau and ptau in normal healthy
subjects. Thus the increase in CSF tau and ptau observed in
AD likely reflects a combination of neuronal cell death and
active secretion.
The molecular nature of tau in CSF is also unknown. Various
reports suggest that fragments of tau are present in CSF,
though the exact identity of these fragments is not defined
[7,22,27,32,33,34,35,36,37]. The majority of CSF tau and ptau
data reported in the literature is based on two related
commercially available assays, INNO-BIA AlzBio3 and the
INNOTEST plate ELISAs [38,39]. In these assays, total tau and
ptau measurements are dependent on anti-tau antibodies
(AT120, HT7 and BT2) specific for the mid-domain region of
the protein (Table 1). The potentially limited range of tau
species measured by these assays, given evidence for the
presence of tau fragments, raises concerns regarding the effect
this could have on diagnostic accuracy and outcome
measures. Additional tools to enable a more comprehensive
analysis of tau and ptau species in CSF are clearly needed.
In this study, we developed a sensitive western-blotting
method to characterize the tau profile in CSF. In addition, we
developed a set of novel overlapping tau and ptau ELISAs to
measure different tau and ptau species and to evaluate the
ability of these to discriminate between AD and control CSF
samples. Results from the western-blotting analysis
demonstrate that CSF tau is composed of a series of fragments
while results from the ELISAs suggest that discriminatory
potential of tau and ptau is dependent on the particular species
measured.
Results
Tau fragments detected in human CSF by western-
blotting
To determine the nature of tau in human CSF, a reverse-
phase high performance liquid chromatography column (RP-
HPLC) was used to enrich the relatively low abundance tau
protein prior to western-blot analysis. Equal volumes of pooled
control and AD CSF samples were fractionated and then
western-blots analyzed with antibodies specific for different
regions of the protein; a summary of the antibodies used is
shown in Table 1. A range of bands were detected with HT7,
an antibody specific for a mid-domain epitope (amino acids
(aa) 159-163; amino acid numbering based on human tau 441)
(Figure 1A). The majority of bands present in fractions 3 to 7
were specific for HT7, as these were not detected with the
IgG1 isotype control antibody (Figure 1D). These bands
exhibited a range of apparent molecular weights (MWs), from <
20 kDa to ~40 kDa, suggesting the presence of tau protein
fragments. Interestingly, tau-specific bands that comigrated
with the tau441 standard (~65 kDa) were not detected
suggesting that full length tau is not present. A subset of the
HT7-immunoreactive bands in fractions 6 to 8 was also
detected with the N-terminal antibody Tau12 (epitope aa 9-18)
indicating that these fragments span both N-terminal and mid-
domain regions of tau (Figure 1B). In addition, bands only
detected with Tau12 were also observed in fractions 6 and 7
providing evidence that truncated N-terminal tau fragments are
also present. Consistent with the HT7 findings, bands of ~65
kDa were not detected with Tau12, confirming the lack of full-
length tau in CSF. Interestingly, the overall tau fragment
pattern observed with both HT7 and Tau12 was similar in AD
compared to control.
Fractions were also analyzed for the presence of C-terminal
fragments using the rabbit polyclonal antibody K9JA, which
Table 1. Tau and ptau antibodies.
Clone Vendor Cat # Epitope1 Species Reference
BT2 Thermo Scientific MN1010 194-198 Mouse [38,49]
HT7 Thermo Scientific MN1000 159-163 Mouse [38]
Tau5 Covance SIG-39413 218-225 Mouse [52,53]
Tau12 Covance SIG-39416 9-18 Mouse [54]
KJ9A Dako A 0024 243-441 Rabbit  
77G7 Covance SIG-39405 316-3352 Mouse this paper
PHF6 Covance SIG-39430 pT231 Mouse [55]
AT270 Thermo Scientific MN1050 pT181 Mouse [56]
IgG Abcam ab81032 NA Mouse NA
1. Amino acid numbering based on human tau 441 sequence
2. Epitope mapping included in Supplemental methods and Figure 1 and Figure 2.
NA: not applicable
doi: 10.1371/journal.pone.0076523.t001
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binds to the microtubule repeat and C-terminal flanking region
of tau (aa 243-441). K9JA exhibited robust staining of full
length tau441 standard (Figure 1C); however, unlike HT7 and
Tau12, K9JA-specific tau bands were not detected in the CSF
samples (Figure 1C). Similar results were also observed with
the MTBR-specific antibody 77G7 (data not shown). A set of
bands of 60-65 kDa were detected at various levels in all of the
fractions (Figure 1C), though these are likely due to nonspecific
immunoreactivity as they were detected to a lesser degree with
the isotype control antibody (Figure 1D), and appear to be due
to cross-reactivity with contaminating keratin (data not shown);
the lack of full length tau is also consistent with ELISA data
discussed below. Taken together, these results indicate that
tau in both control and AD CSF is present as a set of primarily
N-terminal and mid-domain fragments.
Tau fragment and ptau assays
To more accurately quantify CSF tau levels, a set of novel
tau and ptau ELISAs were developed (Figure 2). Assays were
designed to measure overlapping regions of tau using different
combinations of tau and ptau antibodies (Table 1). Each assay
requires different minimal regions of tau, as defined by the
epitopes of the antibodies used, and thus will measure tau
fragments containing these regions. The minimal regions of the
tau assays are aa 9-163 (Tau12-HT7), aa 9-198 (Tau12-BT2),
aa 159-198 (HT7-BT2), aa 159-225 (HT7-Tau5), aa 159-335
(HT7-77G7); the minimal regions of the ptau assays are aa 9-
p181 (Tau12-AT270), aa 159-p181 (HT7-AT270) and aa 159-
p231 (HT7-PHF6) (Figure 2).
The HT7-BT2, HT7-Tau5, Tau12-BT2 and Tau12-HT7 tau
assays demonstrated ~100-fold dynamic range of quantitation
using tau 441 standard, with the LLQ ranging from 1.6 pg/ml to
7.8 pg/ml (Figure 3). Signal from pooled AD and control CSF
samples were within the dynamic range of the HT7-BT2 assay
when diluted 2- to 64-fold (left panel, Figure 3A). Consistent
dilution-corrected tau levels were observed with CSF dilutions
ranging from 16- to 64-fold; similar results were observed for
both AD and control samples (right panel, Figure 3A). A dilution
of 30-fold was identified as optimal for CSF sample analysis.
Similar results were observed for HT7-Tau5, Tau12-BT2 and
Tau12-HT7 (Figure 3B, C, D, respectively) with optimal CSF
dilutions of 10-fold, 25-fold and 20-fold, respectively. Tau
specificity in each assay was verified based on immuno-
depletion (Figure S3) and spike recovery (Figure S4). Taken
together, these results confirm the ability of these assays to
accurately measure tau in CSF.
The HT7-77G7 assay is specific for tau species containing
more C-terminal sequences (aa 159-335). The dynamic range
and LLQ observed (16 pg/ml) were similar to the other tau
ELISAs (Figure 4); however, a HT7-77G7 signal was not
detected in either the pooled control or pooled AD samples,
regardless of sample dilution (Figure 4). The lack of signal was
not an artifact of matrix interference as robust recovery of a
100 pg/ml tau 441 spike was observed in both control and AD
CSF over a range of dilutions (Figure 4). These results indicate
Figure 1.  Detection of tau fragments in human CSF.  Human control and AD CSF subjected to RP-HPLC, fractions collected
and run on SDS-PAGE gels followed by western-blotting with different tau antibodies. A) HT7 (mid domain antibody). B) Tau 12 (N-
terminal antibody). C) K9JA (C-terminal microtubule repeat domain antibody). D) IgG1 isotype control. On each blot, human
recombinant tau441 (tau) is included in lane 1 and molecular weight markers (mw) in lane 2 followed by the HPLC fractions from 1
to 6 or HPLC fractions 7 to 11. Fractions 1 and 2 were pooled and run as a single sample, while fractions 3-10 were run as
individual samples. Control CSF (C) and AD CSF (D) samples for each fraction were run side by side for comparison.
doi: 10.1371/journal.pone.0076523.g001
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that tau species containing the region aa 159-335 are not
present in these pooled CSF samples at levels >16 pg/ml.
All three ptau assays, HT7-AT270, Tau12-AT270 and HT7-
PHF6, demonstrated ~100-fold dynamic range of quantitation
using synthetic ptau standards, with LLQs ranging from 2 pg/ml
to 7.8 pg/ml (Figure 5). In the HT7-AT270 assay, consistent
dilution-corrected ptau levels were observed in AD and control
CSF with dilutions ranging from 2- to 16-fold (right panel,
Figure 5A). In the Tau12-AT270 assay (Figure 5B) and HT7-
PHF6 assays (Figure 5C), dilution linearity was observed when
samples were measured neat or diluted up to 4-fold. CSF ptau
signal specificity was verified by a combination of immuno-
depletion and peptide competition (Figure S5) and spike
recovery (Figure S6). Taken together, these results confirm
specificity of the ptau signal measured in these assays.
Evaluation of CSF tau and ptau in a cohort of control
and AD CSF samples
To evaluate the discriminatory power of the assays, tau and
ptau levels were measured in a cohort of 20 AD and 20 age-
matched control CSF samples (20x20 sample set);
demographic information included in Table 2. The relative
ability of each assay to detect differences between AD and
control samples was assessed using Student’s t-test
comparison of log-transformed data. Differences were deemed
significant for p < 0.01. Samples were also benchmarked for
Aβ42, tau and p181tau using INNO-BIA AlzBio3. Levels of CSF
Aβ42 were significantly reduced while levels of tau and ptau
were significantly increased in AD samples compared to the
age-matched controls when measured using INNO-BIA AlzBio3
(Figure S7; Table 3), consistent with expectations for a typical
AD vs control sample set.
In the tau ELISAs, the highest CSF tau levels were detected
using the HT7-BT2 assay, specific for tau species containing
aa 159-198. In comparison, levels of tau species containing
additional N-terminal sequence (aa 9-198, Tau12-BT2; aa
9-163, Tau12-HT7) were 2- to 4-fold lower, while tau species
containing additional C-terminal sequence (aa 159-225, HT7-
Tau5) were 3-fold lower (Table S1). Levels measured in these
assays were highly correlated (r2 = 0.87-0.95) (Table S2). On
the other hand, tau containing additional C-terminal sequence
aa 159-335 (HT7-77G7) could not be detected (Figure 6),
consistent with results from the pooled samples (Figure 4). A
signal above background was detected in 11 of the 20 AD
samples and 3 of the 20 control samples though additional
work will be needed to quantify and verify the specificity of this
HT7-77G7 signal.
Overall, CSF tau levels were found to be significantly higher
in AD samples compared to controls in all but the HT7-77G7
assay (Figure 6; Table 3). The most significant differences
were observed using assays specific for tau containing aa
9-163 (Tau12-HT7) and aa 9-198 (Tau12-BT2), compared to
the difference detected with the HT7-BT2 assay, specific for
tau species containing aa 159-198. Taken together, these
results indicate that the discriminatory power of CSF tau is
dependent on the tau species measured.
The 20x20 samples were also analyzed using the ptau
ELISAs. All three ptau ELISAs exhibited significantly higher
levels in AD compared to control samples, with increases
ranging from 1.4-fold to 2.4-fold (Figure 6; Table 3). Of these,
Figure 2.  Tau and ptau ELISAs.  Schematic of tau 441 protein with the approximate location of various linear epitope antibodies
Tau12, HT7, BT2, Tau5, AT120 and 77G7 and phospho-site specific antibodies AT270 (p181) and PHF6 (p231) indicated;
additional antibody epitope and clone information included in Table 1. Antibody combinations used for the different tau and ptau
ELISAs are shown. For each assay, capture antibodies are highlighted in red, detection antibodies in black and the minimal tau
region required (aa numbering based on tau 441) is indicated. Antibodies used in the INNOTEST/INNO-BIA AlzBio3 total tau and
p181 tau assays are also shown for comparison.
doi: 10.1371/journal.pone.0076523.g002
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Figure 3.  Characterization of tau ELISAs.  Representative tau 441 standard curves (left panels) and CSF dilution linearity results
(right panels) shown for A) HT7-BT2, B) HT7-Tau5, C) Tau12-BT2 and D) Tau12-HT7 tau ELISAs. On each standard curve graph,
tau 441 calibrators (Standards) and results for CSF sample dilutions (Samples) are shown. The assay lower limit of quantitation
(LLQ, vertical dashed line) is also indicated. On each dilution linearity graph, dilution-corrected tau levels for a pooled control CSF
sample and a pooled AD CSF sample relative to sample dilution are shown. The vertical dashed lines indicate the dilution
determined to be optimal for CSF analysis.
doi: 10.1371/journal.pone.0076523.g003
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HT7-AT270, specific for tau species containing aa 159-p181,
exhibited the most significant difference between AD and
control samples. Interestingly, the level of significance was
reduced when p181 was measured in the context of tau
species containing additional N-terminal sequence aa 9-p181
(Tau12-AT270) (p = 0.01, Table 3). Thus, similar to results for
the tau ELISAs, the discriminatory power of CSF p181 is
dependent on the tau species measured. Significant
discrimination of AD from control samples was also observed
using HT7-PHF6, specific for aa 159-p231, though less than
observed with the HT7-AT270 assay. In comparison to the tau
ELISA results, a weaker degree of correlation was observed
using the ptau measures (Table S1). Of the 3 assays, HT7-
AT270 demonstrated the highest degree of correlation with the
tau assays (r2 =0.67-0.72). By comparison, the HT7-PHF6 and
Tau12-AT270 correlations were less robust (r2 =0.18-0.37) and
in some cases not significant.
To further compare the discriminatory power of the different
tau and ptau assays, all possible combinations of tau and ptau
ratios were calculated for each individual CSF sample and then
these values used to evaluate differences and discrimination
between AD and control samples (Table 3, Table S1, Table
S3). This analysis of ratios enables comparison of the relative
disease-associated changes between different assays. Of all
the ratios analyzed, only two, HT7-BT2/HT7-Tau5 and HT7-
BT2/Tau12-HT7, exhibited significant differences between AD
and control (Table S1). In contrast, HT7-Tau5/Tau12-HT7
levels in AD and control samples were nearly identical (Table
S1). These results further support the idea that discrimination
of AD from controls is dependent on the subset of CSF tau
species measured.
Discussion
In this study, tau profiles and the relative differences in tau
and ptau levels between AD and age-matched control CSF
samples were investigated using a combination of qualitative
and quantitative biochemical assays. A sensitive western-
blotting method was used to demonstrate that tau is present in
CSF as a series of N-terminal and mid-domain fragments.
Results from a set of novel ELISAs specific for different
overlapping regions of tau demonstrated that the ability of CSF
tau and ptau to differentiate AD from control is dependent on
the tau species measured. These endpoints provide novel tools
to investigate CSF tau in AD and other neurodegenerative
disorders.
A number of previous studies have reported on the
characterization of tau in CSF using western-blotting-based
techniques; however, results from these studies are mixed and
incongruent [7,22,27,32,33,34,35,36,37,40,41]. Many studies
report the presence of tau fragments in CSF, though the size,
number and prevalence of these fragments vary. Many also
report the presence of full-length tau and in two studies only
full-length tau was detected [40,41]. Some of the discrepancies
between studies may be due to nonspecific binding artifacts
commonly observed with western-blotting. We have identified a
number of nonspecific binding activities in fractionated samples
with various tau-specific antibodies (data not shown). Indeed,
such nonspecific artifacts may account for some of the findings
reported ( [35,36]; see 42). In some studies, incorporation of an
immunoprecipitation step was used to enrich tau prior to
western-blotting, potentially limiting the tau fragments detected
[7,33,40]. And use of postmortem CSF [27,37] may have
compromised analysis as CSF tau levels are highly sensitive to
the integrity of brain tissue [43].
To address these limitations, RP-HPLC was utilized to enrich
and concentrate tau from a large volume of pooled, denatured
CSF thereby enabling analysis of the relatively low levels of tau
by western-blotting. N-terminal and mid-domain tau fragments
were detected in both AD and control CSF, ranging in size from
<20 kDa to ~40 kDa. In contrast, C-terminal-containing
fragments were not detected using the K9JA polyclonal
antibody. Furthermore, full-length tau was not detected with
any of the antibodies tested. The lack of detectable C-terminal
fragments was surprising given reports indicating that MTBR-
containing fragments are present in CSF [22,44,45]. We
confirmed the ability to fractionate and detect full-length tau
Figure 4.  Characterization of HT7+77G7 tau ELISA.  Representative tau 441 standard curve (left panel) and CSF dilution linearity
results (right panel) shown. On the standard curve graph, tau 441 calibrators (Standards) and results for CSF sample dilutions
(Samples) are shown. The assay lower limit of quantitation (LLQ, vertical dashed line) is also indicated. On the dilution linearity
graph, tau levels for a pooled control and pooled AD CSF samples tested with or without a 100 pg/ml tau 441 spike are shown.
doi: 10.1371/journal.pone.0076523.g004
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and MTBR-containing fragments using purified standards (data
not shown). The lack of detectable C-terminal fragments could
be due to limited sensitivity of K9JA to detect these by western-
blot (~30-100 pg) or the inability to resolve higher order
oligomers or aggregates using the RP-HPLC system. Thus,
additional enrichment methods and C-terminal-specific
monoclonal antibody reagents will be needed to help resolve
these issues. Nevertheless, these results demonstrate that
CSF tau is composed of a complex mixture of fragments.
Tau is a putative substrate for various proteases such as
calpain, caspases, cathepsins and thrombin (reviewed in
Table 2. Demographics of 20x20 CSF sample set.
 Control AD
n 20 20
Age at LP (SD), yr 68 (6) 72 (6)
Gender F/M 10/10 10/10
MMSE (SD) 30 (0.5) 21 (4)
doi: 10.1371/journal.pone.0076523.t002
Figure 5.  Characterization of ptau assays.  Representative ptau standard curves (left panels) and CSF dilution linearity results
(right panels) shown for A) HT7-AT270, B) HT7-PHF6, and C) Tau12-AT270 ptau ELISAs. On each standard curve graph, ptau
calibrators (Standards) and results for CSF sample dilutions (Samples) are shown. The assay lower limit of quantitation (LLQ,
vertical dashed line) is also indicated. On each dilution linearity graph, dilution-corrected ptau levels for a pooled control and a
pooled AD CSF samples relative to sample dilution are shown. The vertical dashed lines indicate the dilution determined to be
optimal for CSF analysis.
doi: 10.1371/journal.pone.0076523.g005
Novel CSF Tau and Ptau Biomarkers for AD
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46,47). Tau fragments observed in CSF could be a direct result
of processing by these proteases. Indeed, cleavages at many
of the known sites may partly explain differences in absolute
levels detected in the different tau ELISAs [46,47,48]. However,
technical issues related to the range of tau species present and
the relative affinity of antibodies for those species could also
contribute to assay differences. Thus, comparisons of absolute
levels between ELISAs must be interpreted with caution.
In order to investigate discriminatory potential, each ELISA
was evaluated for its ability to differentiate between 20 AD and
20 matched control CSF samples. In general, all of the tau
ELISAs, with the exception of HT7-77G7, behaved in a similar
manner exhibiting significant (p≤0.01) differences in levels
between AD and control. These findings are consistent with the
high degree of correlation between assays. Despite the
similarities, however, subtle differences in tau assay
performance were also noted. Most interesting was the fact
that the two assays specific for tau species containing N-
terminal sequences, aa 9-163 (Tau12-HT7) and aa 9-198
(Tau12-BT2), exhibited the highest degree of differentiation (p
values of <0.0001 and 0.0001, respectively). In comparison,
differentiation was less robust (p = 0.0031) with HT7-BT2,
specific for aa 159-198. This difference could be partly linked to
Table 3. Summary of analysis of 20x20 CSF sample set.
   
Raw data,
pg/ml1 Log transformed data1
Assay ControlAD Control AD
Fold-
diff
p-
value2
AlzBio
3 Aβ42  
262
(57)
184
(78)
2.409
(0.096)
2.225
(0.192) 0.65 0.0005
 Tau  48(17)
99
(66)
1.662
(0.143)
1.920
(0.257) 1.8 0.0003
 pTau  23 (7) 46(28)
1.330
(0.147)
1.591
(0.249) 1.8 0.0003
Tau Tau12-HT7
(aa
9-163)
312
(95)
714
(497)
2.474
(0.137)
2.773
(0.267) 2.0 <0.0001
 Tau12-BT2
(aa
9-198)
591
(194)
1162
(639)
2.747
(0.155)
3.011
(0.223) 1.8 0.0001
 HT7-BT2 (aa159-198)
1556
(563)
2546
(1914)
3.112
(0.153)
3.330
(0.268) 1.7 0.0031
 HT7-Tau5 (aa159-225)
379
(185)
1019
(888)
2.630
(0.159)
2.943
(0.308) 2.1 0.0003
 HT7-77G7 (aa159-335) <LLQ <LLQ     
pTau HT7-AT270
(aa 159-
p181)
46
(15)
81
(44)
1.646
(0.132)
1.856
(0.208) 1.6 0.0005
 HT7-PHF6
(aa 159-
p231)
18
(18)
43
(28)
1.122
(0.331)
1.501
(0.382) 2.4 0.0018
 Tau12-AT270
(aa 9 -
p181) 21 (7)
29
(10)
1.306
(0.162)
1.439
(0.148) 1.4 0.0100
1. Data based on n = 20 control, n = 20 AD samples. Values represent mean (SD)
2. p-values based on unpaired, 2-tailed Student’s t test comparison of log
transformed control and AD data
LLQ: Lower limit of quantitation
doi: 10.1371/journal.pone.0076523.t003
the sensitivity of BT2 to phosphorylation at S199 [49] as levels
of p199 are reported to be increased in AD CSF [11]. However
BT2 sensitivity cannot account for differences between Tau12-
BT2 and HT7-BT2. Taken together these findings suggest that
N-terminal-containing tau species may be more sensitive
biomarkers of AD. Additional N-terminal assays and larger
sample cohorts will be needed to confirm these results.
Another interesting finding was the lack of a quantifiable CSF
signal in the HT7-77G7 assay. This was not an assay artifact
as complete recovery of a tau spike in CSF matrix was
observed. Given the relatively robust signal measured in the
HT7-Tau5 assay (aa 159-225), the lack of signal in the
HT7-77G7 assay (aa 159-335) suggests extensive cleavage of
tau between the Tau5 (aa 218-225) and 77G7 (aa 316-335)
epitopes, further supporting the idea that CSF tau is
fragmented. The HT7-77G7 result is also consistent with the
inability to detect full-length tau by western-blotting. This was
further confirmed using another ELISA, Tau12-DC39, specific
for tau containing aa 9-441 [43]. As comparable to HT7-77G7,
a tau signal could not be detected in CSF although a tau441
spike was readily measured (data not shown). The lack of a
quantifiable HT7-77G7 signal in CSF, however, does not
exclude the possibility that tau fragments containing MTBR
sequences only or more C-terminal regions are present as
these would be undetectable by the HT7-77G7 assay;
additional C-terminal-specific assays will be needed to fully
explore this idea.
Of the ptau ELISAs evaluated, the HT7-AT270 (aa 159-
p181) assay exhibited the highest level of discrimination,
though only slightly better than HT7-PHF6 (aa 159-p231). This
finding is consistent with data reporting that p181, p231 and
p199 were equivalent in their ability to discriminate AD from
controls [11]. Interestingly, differentiation of AD from control
was partially lost when p181 was measured in the context of
tau species containing additional N-terminal sequence aa 9-
p181 (Tau12-AT270). This finding is surprising given that the
tau ELISAs dependent on the same N-terminal regions
exhibited the most significant differences between the sample
sets. These results suggest that there may be distinct
pathways leading to increased CSF levels of these tau and
ptau species.
In summary, our results indicate that tau is present in control
and AD CSF as a mixture of fragments. Results from our novel
tau and ptau assays provide evidence that the discrimination of
AD from control is dependent on the subset of tau species
measured and that development of more robust AD biomarkers
may be possible. One limitation of the study is the relatively
small sample set used. Ultimate confirmation of these findings
will require analysis of larger cohorts of AD and control
samples to ensure robust statistical analysis. Additional assays
and reagents will also be needed to fully investigate any C-
terminal fragments or aggregates present but not detected by
the methods employed here. Finally, these results could have
implications in the development of CSF tau and ptau
biomarkers for other neurodegenerative diseases, including
other tauopathies where disease-associated changes in tau
and ptau have not been consistently observed.
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Methods
Ethics statement
The study was approved by the regional ethics committee at
the University of Gothenburg.
CSF samples
Pooled control and pooled AD CSF samples were generated
by board-certified laboratory technicians at the Clinical
Neurochemistry Laboratory, the Sahlgrenska University
Hospital in Mölndal, Sweden. Samples were categorized as
control or AD on the basis of CSF tau, ptau and Aβ42 cut-
points that are 90% sensitive and specific for AD (tau > 350
ng/L, ptau > 80 ng/L and Aβ42 < 530 ng/L; biomarker
concentrations derived using INNOTEST ELISAs
(Innogenetics, Ghent, Belgium)) [4].
Individual AD and age-matched CSF samples were
purchased from Precision Med (Solana Beach, CA). Written
and verbal consents were obtained from participants at
screening and enrollment. For all patients, participants were >
55 years of age, in good general health having no other
neurological, psychiatric or major medical diagnosis that could
contribute significantly to cognitive impairment or dementia. For
AD, patients were selected based upon a probable diagnosis of
AD using NINCDS-ADRA criteria, a Hachinski score < (and
equal to) 4 and with an MMSE between 14-26. Control subjects
Figure 6.  Tau and ptau levels in 20 AD and 20 control CSF samples.  A set of 20 AD and 20 age-matched normal control CSF
samples were analyzed using the tau ELISAs (HT7-BT2, HT7-Tau5, Tau12-BT2, Tau12-HT7 and HT7-77G7) and pTau ELISAs
(HT7-AT270, HT7-PHF6 and Tau12-AT270). Dashed lines indicate the assay LLQ corrected for CSF dilution. Statistics based on 2-
tailed Student’s t test comparison of log-transformed data, * p < 0.05; ** p< 0.01; *** p < 0.001.
doi: 10.1371/journal.pone.0076523.g006
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were classified as healthy, but no cognitive testing was
performed. The complete demographic and individual data for
these samples are shown in Tables S4 and S5, respectively.
HPLC fractionation of CSF for western-blotting
Human CSF was denatured in guanidine-HCl (VWR, West
Chester, PA) to a final concentration of 6 M guanidine-HCl. 24
ml injections of the denatured CSF (6 ml CSF + 18 ml
guanidine-HCl) were fractionated with an Agilent 1100 series
HPLC running at 1.5 ml/min over a Poros R1/10 protein column
(4.6 mm X 100 mm, Applied Biosystems, Foster City, CA)
heated to 65°C. 30 x 2 ml fractions were collected for each
sample using an water/acetonitrile gradient (0-60% acetonitrile
over 35 min) in the presence of 0.1% (volume/volume)
trifluoroacetic acid. Fractions were dried to completion in a
SpeedVac Explorer (Thermo Savant, Pittsburgh, PA) overnight.
Dried fractions were stored at -20°C until analysis. A similar
strategy was used previously to extract and enrich Aβ peptides
from human plasma and CSF and to eliminate matrix
interference [50,51].
Western-blotting of fractions
Dried HPLC fractions were resuspended in tricine sample
buffer, and separated on Novex 10-20% tricine gels according
to manufacturer’s directions. Gels were transferred onto 0.45
µm polyvinylidene difluoride (PVDF) membrane (Invitrogen,
Carlsbad, CA) in CAPS transfer buffer (pH 11.0) at room
temperature for 90 min. Membranes were blocked in TBST
(Tris-buffered saline with 0.1% (v/v) Tween-20) with 1% BSA
(Thermo, Rockford, IL) for 1 hr. Membranes were probed with
HT7 (Pierce), Tau12 (Covance, Dedham, MA), KJ9A (Dako,
Carpinteria, CA), and mouse IgG1 monoclonal isotype control
(Abcam, Cambridge, MA) conjugated to HRP (LYNX Rapid
HRP Antibody Conjugation kit, AbD Serotec, Oxford, UK) in
TBST with 1% BSA for 16 hrs at room temperature. Probed
membranes were developed using SuperSignal West Femto
Maximum Sensitivity Substrate (Pierce, Rockford, IL).
INNO BIO AlzBio 3
INNO BIO AlzBio 3 was used to measure CSF Aβ(1-42)
(Aβ42), tau and p-tau (181) according to the manufacturer’s
instructions (Innogenetics, Ghent, Belgium). Briefly, suspension
array bead sets were incubated with reference standards, QC
samples, human CSF along with biotinylated reporter
overnight. Excess unbound material was removed via vacuum
filtration, followed by incubation with streptavidin-phycoerythrin
(PE) for 60 min. The antibody/peptide complexes were
detected via PE fluorescence as measured by a Bio-Rad
BioPlex instrument running Luminex xPonent software. Analyte
levels were quantified using an unweighted 4-parameter
logistic (4PL) curve fit generated from the reference standards
using BioPlex manager 5.0 software
CSF tau ELISAs
Tau ELISAs were developed using the following mouse
monoclonal antibodies for capture; antibody information listed
in Table 1. Tau12 (aa 9-18, SIG-39416, Covance, Princeton,
NJ), HT7 (aa 159-163, MN1000, Thermo Scientific,Rockford,
IL) or BT2 (aa 194-198, MN1010, Thermo Scientific,Rockford,
IL). The respective analytes were detected using the following
alkaline phosphatase (AP) conjugated mouse monoclonal
antibodies: BT2, HT7, Tau5 (aa 218-225, SIG-39413, Covance,
Princeton, NJ) or 77G7 (aa 316-335, SIG-34905, Covance,
Princeton, NJ). Eptiope mapping for 77G7 is included in
Supplemental methods and Figures S1 and S2. Human tau441
(tau441) recombinant protein (rPeptide, Bogart, GA) was used
to generate standard curves for each of the assays. Standards
were run in two-fold serial dilutions in assay buffer containing
1% BSA (w/v) and 0.05% tween-20 (v/v) in Tris buffered saline
(TBS), pH 8. The tau441 standard curve range for each of the
ELISAs was 400-2 pg/ml (Tau12-BT2 and HT7-Tau5), 1000-16
pg/ml (Tau12-HT7), 1000-4 pg/ml (HT7-BT2), 1000-8 pg/ml
(HT7-77G7). Human CSF dilution linearity curves were run for
each of the tau ELISAs with CSF at 2-fold serial dilutions from
2- to 64-fold to determine the optimal sample dilution for each
of the assays. Based on the results from the CSF linearity
experiment, individual CSF samples were assayed at the
following dilutions in assay buffer for each of the total tau
assays: 2-fold (HT7-77G7), 20-fold (Tau12-HT7), 10-fold (HT7-
Tau5), 25-fold (Tau12-BT2), 30-fold (HT7-BT2).
Immunodepletion and spike recovery samples were generated
as described (Supplemental methods).
Tau ELISAs were run as follows. High binding black 96 well
plates (Costar 3925, Corning, NY) were coated by the addition
of 2.5 µg/ml (BT2, HT7) or 5 µg/ml (Tau12) capture antibodies
which were diluted in Tris buffered saline (TBS), pH 8. Plate
sealers were attached then the plates were incubated at 37°C
for 1 hr. Plates were washed with TBST (TBS containing 0.05%
Tween-20) before blocking nonspecific binding sites with 3%
bovine serum albumin (BSA; protease free, fraction V; Roche
Biochemicals, Indianapolis, IN) (w/v) in TBS. Plate sealers
were attached and the plates were incubated at room
temperature for 2-4 hrs while shaking. Plates were washed with
TBST before the addition of 50 µl per well diluted human CSF
and human tau441 standard curves which were each prepared
in a final assay buffer concentration of 1% BSA (w/v) and
0.05% Tween-20 (v/v) in Tris buffered saline (TBS), pH 8. Plate
sealers were attached, then assay plates containing human
CSF and standard curves were incubated overnight at 4°C
while shaking. Alkaline phosphatase (AP) conjugated BT2,
HT7, Tau5 or 77G7 antibodies were diluted into assay buffer
before being added to the assay plate (50 µl per well) to co-
incubate with human CSF and htau441 standard curves for 1
hr at room temperature while shaking. Plates were washed with
TBST before being developed using alkaline phosphatase
substrate (T2214; Applied Biosystems, Foster City, CA).
Luminescence counts were measured using a Packard
TopCount (PerkinElmer, MA). Log-transformed luminescence
counts from individual samples were interpolated to
concentration using a second-order polynomial fit to the
respective standards (GraphPad Prism 5.00, GraphPad
Software, San Diego, CA). CSF tau levels were plotted after
correction for dilution factor in the respective assays. Assay
lower limit of quantitation (LLQ) was set based on the lowest
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calibrator demonstrating acceptable total error (bias + precision
of < 30%).
Human Tau441 Spike Recovery in HT7-77G7 ELISA
A pooled CSF sample from AD patients and an age-matched
pooled control CSF sample were 2-fold serially diluted from 2-
to 256-fold in a final assay buffer concentration of 1% BSA
(w/v) and 0.05% tween-20 (v/v) in Tris buffered saline (TBS),
pH 8 before an aliquot of each was spiked with recombinant
human tau441 protein (rPeptide, Bogart, GA) at a final
concentration of 100 pg/ml. Diluted CSF samples with and
without tau441 spike were assayed in the HT7-77G7 ELISA as
described above.
CSF ptau ELISAs
Human CSF was analyzed in three different ptau assays:
HT7-AT270 (p181) and HT7-PHF6 (p231) and Tau12-AT270
(p181). The HT7-AT270 and HT7-PHF6 ELISAs utilized HT7
(amino acids 159-163), while the Tau12-AT270 assay used
Tau12 (amino acids 9-18), as the capture antibody, and the
respective analytes were detected using alkaline phosphatase
(AP) conjugated AT270 pT181 tau antibody (MN1050, Thermo,
Rockford, IL) or PHF6 pT231 specific monoclonal antibody
(SIG-39430, Covance, Dedham, MA); antibody information
listed in Table 1. Standards for the 3 different assays were
custom synthesized (Abgent Inc., San Diego, CA) and
contained sequences with the respective capture and detection
epitopes as follows: the HT7-AT270 and HT7-PHF6 assay
standards used native human tau sequence of aa 155–207 and
aa 155–236, respectively, with the Thr181 and Thr 231
residues being phosphorylated; the Tau12-AT270 assay
standard consisted of aa 5-28 linked with a polyethylene glycol
(PEG12) linker to aa 174-187, with a phosphorylated Thr181
residue. Standard purity was verified at the Keck Biotechnology
Resource Laboratory at Yale University. Standards were run in
2-fold serial dilution in assay buffer containing 0.3% BSA in
PBS with 0.05% Tween, with a range of 125 to 1 pg/ml for
HT7-AT270, and 500 to 4 pg/ml for HT7-PHF6 and Tau12-
AT270 tau assays. CSF samples were run neat for the
HT7+pT231 tau assay, while the Tau12+pT181 and
HT7+pT181 tau assays were run at 2- and 4-fold dilution in
assay buffer. Immunodepletion and spike recovery samples
were generated as described (Supplemental methods).
pTau ELISAs were run as follows. Black high-binding plates
(Costar, Corning, NY) were coated with 2.5 µg/ml of capture
antibodies HT7 or Tau12 in carbonate-bicarbonate buffer at pH
9.4 (Thermo, Rockford, IL). After overnight incubation at 4°C,
plates were washed with PBS and nonspecific binding sites
were blocked using 3% BSA in PBS buffer for at least 4 hrs at
4°C. Standards and CSF samples (50 µL) were added to
plates, followed by 50 µL of AP conjugated AT270 (pThr181)
and PHF6 (pThr231) tau antibodies for the respective assays.
After overnight incubation at 4°C, plates were washed with
PBS (containing 0.05% tween) and developed using alkaline
phosphatase substrate (T2214; Applied Biosystems, Foster
City, CA). Luminescence counts were measured using
Envision (PerkinElmer, MA). Log-transformed luminescence
counts from individual samples were interpolated to
concentration using a 3rd order polynomial fit to the respective
standards (GraphPad Prism 5.00, GraphPad Software, San
Diego CA) CSF ptau levels were plotted after correction for
dilution factor in the respective assays. Assay lower limit of
quantitation (LLQ) was set based on the lowest calibrator
demonstrating acceptable total error (bias + precision of <
30%).
Statistics
Statistical calculations were performed using GraphPad
Prism 5.00 (GraphPad Software, San Diego, CA). Differences
in biomarker levels between AD and control samples were
examined using unpaired two-tailed Student’s t-test. Data was
log-transformed prior to t-test comparisons to correct for non-
Gaussian distributions as determined by the D’Agostino &
Pearson normality test. Results were considered significant for
p-values < 0.01
Supporting Information
Figure S1.  Tau peptides used for 77G7 antibody epitope
mapping. A set of 29 overlapping peptides spanning the length
of human tau 441 were generated, coupled to beads and used
to map the epitope of tau antibody 77G7 using a Luminex-
based multiplex assay.
(DOCX)
Figure S2.  Mapping the tau epitope of antibody 77G7. Left
panel) 77G7 exhibited binding to human Tau 441 and the C-
terminal human tau fragment aa 231-441 but not to the tau
fragments aa 1-125 or aa 126-230; 77G7 also bound to the
other tau isoforms (data not shown). Mid-domain tau antibody
HT7 exhibited binding to tau 441 and fragment aa 126-230 as
expected. Binding was not observed with the anti-IL6 control
antibody. Right panel) A set of 29 overlapping peptides
spanning the length of human tau 441 were generated, coupled
to beads and used in a Luminex-based multiplex assay to
screen 77G7, HT7 and anti-IL6 control. 77G7 exhibited binding
to peptide 22 (aa 316-335) and much lower level binding to
peptide 25 but none of the other peptides (right panel and data
not shown). HT7 exhibited binding to peptide 11 (aa 150-170)
but none of the other peptides (right panel and data not shown)
as expected while the control anti-IL6 antibody did not react
with any of the peptides tested.
(DOCX)
Figure S3.  Verification of signal specificity in tau ELISAs
by immunodepletion. Pooled CSF was immunodepleted with
tau antibody HT7 (IP) or treated with protein A/G beads alone
(control). Samples were analyzed in tau ELISAs A) HT7-BT2,
B) HT7-Tau5, C) Tau12-BT2 and D) Tau12-HT7. Data
represents mean ± SEM from 3-4 determinations. Dashed lines
indicate the assay LLQ corrected for CSF dilution.
(DOCX)
Figure S4.  Spike recovery in tau ELISAs. Pooled CSF
samples were treated with tau 441 spikes ranging from 10-800
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pg/ml. Spiked samples and a matching untreated control were
analyzed in tau ELISAs A) HT7-BT2, B) HT7-Tau5, C) Tau12-
BT2 and D) Tau12-HT7 and spike recovery determined (%).
Data represents mean ± SEM from 3 determinations. Dashed
lines indicate 100% spike recovery.
(DOCX)
Figure S5.  Verification of signal specificity in ptau ELISAs
by immunodepletion and peptide competition. Pooled CSF
samples from healthy control subjects (black bars) or AD
patients (red bars) were immunodepleted with tau antibody
HT7 (IP) or protein A/G beads alone (control). CSF samples
were also treated with pT181 or pT231 peptides for competition
analysis. Samples were analyzed in ptau ELISAs A) HT7-
AT270, B) HT7-PHF6, and C) Tau12-AT270. Data represents
mean ± SEM from 3 determinations. Dashed lines indicate the
assay LLQ corrected for CSF dilution.
(DOCX)
Figure S6.  Spike recovery in ptau ELISAs. Pooled CSF
samples were treated with pT181 or pT231 spikes ranging from
12.5-200 pg/ml. Spiked samples and a matching untreated
controls were analyzed in ptau ELISAs A) HT7-AT270, B) HT7-
PHF6, and C) Tau12-AT270 and spike recovery determined
(%). Data represents mean ± SEM from 3 determinations.
Dashed lines indicate 100% spike recovery.
(DOCX)
Figure S7.  Analysis of tau and ptau levels in 20 AD and 20
control CSF samples. A set of 20 AD and 20 age-matched
normal control CSF samples were analyzed using INNO-BIA
AlzBio3. Statistics based on 2-tailed Student’s t test
comparison of log-transformed data (tau and ptau) or
untransformed data (Aβ42). * p < 0.05; ** p< 0.01; *** p <
0.001.
(DOCX)
Methods S1.  Epitope mapping and immunodepletion and
spike recovery.
(DOCX)
Table S1.  Analysis of tau assay ratios in 20x20 sample set.
(DOCX)
Table S2.  Tau ELISA correlations.
(DOCX)
Table S3.  Analysis of ptau assay ratios in 20 x 20 sample
set.
(DOCX)
Table S4.  Complete demographic information for 20 x 20
sample set.
(DOCX)
Table S5.  Individual data for 20 x 20 sample set.
(DOCX)
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